Literature DB >> 18287270

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Lisa Mosconi1, Wai H Tsui, Karl Herholz, Alberto Pupi, Alexander Drzezga, Giovanni Lucignani, Eric M Reiman, Vjera Holthoff, Elke Kalbe, Sandro Sorbi, Janine Diehl-Schmid, Robert Perneczky, Francesca Clerici, Richard Caselli, Bettina Beuthien-Baumann, Alexander Kurz, Satoshi Minoshima, Mony J de Leon.   

Abstract

UNLABELLED: This multicenter study examined (18)F-FDG PET measures in the differential diagnosis of Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) from normal aging and from each other and the relation of disease-specific patterns to mild cognitive impairment (MCI).
METHODS: We examined the (18)F-FDG PET scans of 548 subjects, including 110 healthy elderly individuals ("normals" or NLs), 114 MCI, 199 AD, 98 FTD, and 27 DLB patients, collected at 7 participating centers. Individual PET scans were Z scored using automated voxel-based comparison with generation of disease-specific patterns of cortical and hippocampal (18)F-FDG uptake that were then applied to characterize MCI.
RESULTS: Standardized disease-specific PET patterns were developed that correctly classified 95% AD, 92% DLB, 94% FTD, and 94% NL. MCI patients showed primarily posterior cingulate cortex and hippocampal hypometabolism (81%), whereas neocortical abnormalities varied according to neuropsychological profiles. An AD PET pattern was observed in 79% MCI with deficits in multiple cognitive domains and 31% amnesic MCI. (18)F-FDG PET heterogeneity in MCI with nonmemory deficits ranged from absent hypometabolism to FTD and DLB PET patterns.
CONCLUSION: Standardized automated analysis of (18)F-FDG PET scans may provide an objective and sensitive support to the clinical diagnosis in early dementia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287270      PMCID: PMC3703818          DOI: 10.2967/jnumed.107.045385

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

2.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Impairment of neocortical metabolism predicts progression in Alzheimer's disease.

Authors:  K Herholz; A Nordberg; E Salmon; D Perani; J Kessler; R Mielke; M Halber; V Jelic; O Almkvist; F Collette; M Alberoni; A Kennedy; S Hasselbalch; F Fazio; W D Heiss
Journal:  Dement Geriatr Cogn Disord       Date:  1999 Nov-Dec       Impact factor: 2.959

4.  Hippocampal formation glucose metabolism and volume losses in MCI and AD.

Authors:  S De Santi; M J de Leon; H Rusinek; A Convit; C Y Tarshish; A Roche; W H Tsui; E Kandil; M Boppana; K Daisley; G J Wang; D Schlyer; J Fowler
Journal:  Neurobiol Aging       Date:  2001 Jul-Aug       Impact factor: 4.673

5.  Hippocampal hypometabolism predicts cognitive decline from normal aging.

Authors:  Lisa Mosconi; Susan De Santi; Juan Li; Wai Hon Tsui; Yi Li; Madhu Boppana; Eugene Laska; Henry Rusinek; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-01-11       Impact factor: 4.673

6.  Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.

Authors:  S Minoshima; N L Foster; A A Sima; K A Frey; R L Albin; D E Kuhl
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

Review 7.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

8.  Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits.

Authors:  Daniel H S Silverman; Sanjiv S Gambhir; Hsuan-Wen C Huang; Judy Schwimmer; Shanna Kim; Gary W Small; Joshua Chodosh; Johannes Czernin; Michael E Phelps
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

9.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

10.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11
View more
  212 in total

1.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.

Authors:  Jia Yao; Ryan T Hamilton; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Biochim Biophys Acta       Date:  2010-06-09

2.  Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease.

Authors:  Lisa Mosconi; Wai Tsui; John Murray; Pauline McHugh; Yi Li; Schantel Williams; Elizabeth Pirraglia; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2011-04-22       Impact factor: 4.673

Review 3.  Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.

Authors:  Catarina Freitas; Helena Mondragón-Llorca; Alvaro Pascual-Leone
Journal:  Exp Gerontol       Date:  2011-04-14       Impact factor: 4.032

Review 4.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

5.  Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Authors:  Mateen C Moghbel; Babak Saboury; Sandip Basu; Scott D Metzler; Drew A Torigian; Bengt Långström; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

6.  Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Authors:  D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-04-29       Impact factor: 2.680

7.  Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

Authors:  José V Pardo; Joel T Lee; Michael A Kuskowski; Kristin R Munch; John V Carlis; Sohail A Sheikh; Christa Surerus; Scott M Lewis; J Riley McCarten; Howard Fink; Susan McPherson; Hemant H Shah; Susan Rottunda; Maurice W Dysken
Journal:  Alzheimers Dement       Date:  2010-05-06       Impact factor: 21.566

Review 8.  FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Authors:  Giovanni Lucignani; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 9.  Mitochondrial function in ageing: coordination with signalling and transcriptional pathways.

Authors:  Fei Yin; Harsh Sancheti; Zhigang Liu; Enrique Cadenas
Journal:  J Physiol       Date:  2015-09-16       Impact factor: 5.182

Review 10.  Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging.

Authors:  Valentina Berti; Lisa Mosconi; Alberto Pupi
Journal:  PET Clin       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.